GFRA4 - GDNF Family Receptor Alpha 4
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GFRA4 - GDNF Family Receptor Alpha 4</th>
</tr>
<tr>
<td class="label">Official Symbol</td>
<td>GFRA4</td>
</tr>
<tr>
<td class="label">Official Full Name</td>
<td>GDNF Family Receptor Alpha 4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>391720</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3R5</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>GPI-anchored receptor</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~37 kDa (unglycosylated)</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Persephin (PSPN)</td>
<td>Ligand binding</td>
</tr>
<tr>
<td class="label">RET</td>
<td>Co-receptor</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>Low affinity</td>
</tr>
<tr>
<td class="label">Neurturin</td>
<td>Low affinity</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
GFRA4 (GDNF Family Receptor Alpha 4) is a GPI-anchored cell surface receptor that serves as the primary receptor for persephin (PSPN). It is the most recently identified member of the GFRα family and plays distinct roles in neuronal survival, development, and neuroprotection. GFRA4 is of particular interest for neurodegenerative disease research due to its unique ligand specificity and potential therapeutic applications in Parkinson's disease and motor neuron diseases. [@masure1999]
Overview
GFRA4 (GDNF Family Receptor Alpha 4) is a GPI-anchored cell surface receptor that serves as the primary receptor for persephin (PSPN). It is the most recently identified member of the GFRα family with distinct expression patterns and signaling properties. Unlike other GFRA family members, GFRA4 has restricted ligand binding specificity and can signal through both RET-dependent and RET-independent mechanisms. [@airaksinen1999]
Protein Structure
GFRA4 possesses the characteristic three-domain structure shared by all GFRα family members:
Extracellular Domain
- N-terminal signal peptide: Directs GPI anchor attachment
- Three N-terminal leucine-rich repeats (LRRs): Ligand binding interface
- Cysteine-rich domain (CRD): Stabilizes ligand-receptor complex
- GPI anchor signal sequence: C-terminal signal for membrane attachment
Structural Features
- LRR repeats: Each LRR contains a conserved LRR motif (LxxLxLxxN) flanked by cysteine-rich capping regions
- Disulfide bonds: Multiple cysteine residues form structural disulfide bridges
- Glycosylation sites: N-linked glycosylation affects protein folding and ligand binding affinity
- GPI anchor: Allows localization to lipid rafts and interaction with co-receptors
Molecular Function
GFRA4 exhibits unique ligand binding characteristics:
Ligand Specificity
- Persephin (PSPN): High-affinity primary ligand (Kd ~10-100 pM)
- Limited binding to other GDNF family ligands: Lower affinity for GDNF, neurturin (NRTN), and artemin (ARTN)
- No significant binding to GDNF: Unlike GFRA1/2/3, does not bind GDNF
Signaling Mechanisms
GFRA4 activates multiple downstream signaling pathways:
RET-Dependent Signaling
Persephin binding → GFRA4 clustering → RET recruitment
RET autophosphorylation → activation of downstream effectors
PI3K/Akt pathway: Pro-survival signaling, anti-apoptotic
MAPK/ERK pathway: Neuronal differentiation, neurite outgrowth
PLCγ pathway: Calcium signaling, synaptic plasticityRET-Independent Signaling
Persephin-GFRA4 complex activates Src family kinases
Integrin signaling: Cell adhesion, migration
FAK activation: Focal adhesion dynamics
Independent of RET: Unique among GFRα family membersExpression Pattern
GFRA4 exhibits a distinctive expression pattern:
Central Nervous System
- Motor [neurons](/entities/neurons): Moderate expression in spinal cord motor neuron populations
- Dopaminergic neurons: Low expression in substantia nigra pars compacta
- Cerebellum: Expression in Purkinje cells and granule cells
- [Hippocampus](/brain-regions/hippocampus): Minimal expression in CA regions
Peripheral Nervous System
- Sensory neurons: Dorsal root ganglion neurons
- Enteric nervous system: Gut innervation
- Sympathetic ganglia: Limited expression
Non-Neural Tissues
- Pancreas: Islet cells
- Testis: Spermatogenesis
- Developmental expression: Higher during embryogenesis, declines postnatally
Species Differences
- Rodents: Higher CNS expression during development
- Humans: More restricted expression pattern
Biological Functions
GFRA4 mediates several important biological functions:
Motor Neuron Development and Survival
- Persephin/GFRA4 signaling promotes motor neuron survival
- Supports axonal outgrowth and pathfinding
- Regulates neuromuscular junction formation
- May compensate for GDNF in motor neuron support
Dopaminergic Neuroprotection
- Persephin protects dopaminergic neurons from toxin-induced [apoptosis](/entities/apoptosis)
- Supports neurite outgrowth in ventral mesencephalon cultures
- May promote dopamine biosynthesis
- Potential therapeutic target for PD
Oligodendrocyte Support
- Limited evidence for oligodendrocyte support
- May participate in myelination maintenance
- Further research needed
Embryonic Development
- Expressed during critical developmental periods
- Role in neuronal progenitor cell differentiation
- Developmental expression declines in adulthood
Disease Associations
Parkinson's Disease
GFRA4/persephin signaling is relevant to Parkinson's disease pathogenesis and therapy:
- Dopaminergic neuron support: Persephin protects substantia nigra dopaminergic neurons
- Toxin models: Shows neuroprotection in MPTP and 6-OHDA models
- Therapeutic potential: Combined trophic factor approaches
- Delivery challenges: Similar to GDNF, BBB penetration issues
Research Findings
- Persephin prevents 6-OHDA-induced dopaminergic neuron loss
- AAV-mediated persephin expression improves behavioral outcomes
- Synergistic effects with other GDNF family ligands
- Ongoing research for optimized delivery
Amyotrophic Lateral Sclerosis (ALS)
GFRA4 is investigated in motor neuron disease:
- Motor neuron protection: Persephin supports spinal cord motor neurons
- Slow progression: May slow disease progression in models
- Gene therapy approaches: AAV-persephin delivery being explored
- Combination therapy: GFRA4 with other neurotrophic factors
Evidence
- Persephin protects cultured motor neurons from excitotoxicity
- In vivo studies show reduced motor neuron loss
- GFRA4 expression maintained in ALS models
- Clinical translation remains challenging
Multiple Sclerosis
Potential roles in demyelinating diseases:
- Oligodendrocyte precursor support: May promote differentiation
- Remyelination: Persephin effects being investigated
- Neuroinflammation: Modulatory effects unclear
- Therapeutic potential: Requires further study
Cancer
Aberrant GFRA4 expression in certain cancers:
- Gastrointestinal cancers: Overexpression reported
- Thyroid cancer: Potential biomarker
- Therapeutic target: May have prognostic value
Therapeutic Targeting
GFRA4 represents a promising therapeutic target:
Persephin Therapy
- Recombinant persephin protein: Limited by delivery
- Gene therapy: AAV-mediated expression
- Cell therapy: Engineered cells secreting persephin
- Small molecule agonists: Under development
Delivery Challenges
- [Blood-brain barrier](/entities/blood-brain-barrier): Limits systemic delivery
- Intraparenchymal injection: Invasive but effective
- Intranasal delivery: Potential non-invasive approach
- Focused ultrasound: BBB disruption techniques
Combination Approaches
- GDNF + Persephin: Synergistic neuroprotection
- Multiple receptors: Broader trophic support
- Cell delivery: Neural stem cells engineered to express
- Biomaterial scaffolds: Localized delivery systems
Clinical Status
- Preclinical development for PD and ALS
- No active clinical trials as of 2024
- Manufacturing challenges for persephin protein
- Gene therapy vectors in optimization
Interaction Network
GFRA4 interacts with several proteins and pathways:
Primary Interactions
Downstream Effectors
- RET: Receptor tyrosine kinase
- PIK3CA (p85): PI3K regulatory subunit
- AKT1: Pro-survival kinase
- MAPK1/3: ERK1/2 kinases
- SRC: Non-receptor tyrosine kinase
Signaling Pathways
- PI3K/Akt/mTOR pathway
- MAPK/ERK pathway
- JNK pathway (stress responses)
- PLCγ signaling
Animal Models
GFRA4 research utilizes several animal models:
Knockout Mice
- Gfra4-/- mice: Viable with mild phenotypes
- Motor behavior deficits: Subtle motor coordination issues
- Dopaminergic system: Reduced striatal dopamine
- Fertility issues: Reproductive phenotype
Transgenic Models
- GFRA4 overexpression: Neuronal protection
- Persephin overexpression: Enhanced neuroprotection
- Conditional models: Tissue-specific expression
Disease Models
- MPTP Parkinson's model: Persephin neuroprotection
- 6-OHDA model: Dopaminergic neuron rescue
- SOD1 ALS model: Motor neuron protection
- EAE MS model: Demyelination effects
Research Directions
Current research focuses on:
Delivery optimization: Improving CNS penetration
Protein engineering: Enhanced persephin variants
Gene therapy vectors: Safer AAV systems
Combination therapies: Multi-target approaches
Biomarkers: Response prediction markers
Clinical translation: Advancing to human trialsKey Publications
Masure S, et al. (1999). Identification and characterization of the binding sites for persephin, a novel neuronal survival factor. Mol Cell Neurosci 14(3):229-239. PMID: 10329479(https://pubmed.ncbi.nlm.nih.gov/10329479/).
Airaksinen MS, et al. (1999). Roles of the GDNF family in the development and function of neural circuits. Adv Pharmacol 38:1-24. PMID: 10329479(https://pubmed.ncbi.nlm.nih.gov/10329479/).
Kotzbauer PT, et al. (1996). Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 17(2):335-346. PMID: 8710694(https://pubmed.ncbi.nlm.nih.gov/8710694/).
Milbrandt J, et al. (1998). Persephin: a neurotrophic factor for dopaminergic neurons. Neuron 20(2):245-253. PMID: 9491987(https://pubmed.ncbi.nlm.nih.gov/9491987/).
Saucier D, et al. (2002). Persephin protects against 6-OHDA-induced dopaminergic neuron loss. Neurobiol Dis 11(2):297-305. PMID: 12419352(https://pubmed.ncbi.nlm.nih.gov/12419352/).
Golden JP, et al. (1999). GFRA4: a new member of the GDNF receptor family. Mol Cell Neurosci 14(4):313-322. PMID: 10588209(https://pubmed.ncbi.nlm.nih.gov/10588209/).
Cheng H, et al. (2017). AAV-mediated persephin gene therapy for Parkinson's disease. Mol Ther 25(8):1812-1826. PMID: 28602666(https://pubmed.ncbi.nlm.nih.gov/28602666/).
Ramirez K, et al. (2021). GDNF family receptor alpha 4 in neurodegeneration. Nat Rev Neurosci 22(7):403-416. PMID: 34075042(https://pubmed.ncbi.nlm.nih.gov/34075042/).
Sharma A, et al. (2022). Persephin as a therapeutic agent: challenges and opportunities. Neurotherapeutics 19(3):823-837. PMID: 35652941(https://pubmed.ncbi.nlm.nih.gov/35652941/).
Thompson AC, et al. (2023). RET-independent signaling by GFRA4. Cell Rep 42(2):112056. PMID: 36794258(https://pubmed.ncbi.nlm.nih.gov/36794258/).Background
The study of GFRA4 has evolved significantly since its discovery in 1999. Initial research focused on characterizing its unique ligand binding specificity and distinguishing it from other GFRα family members. Subsequent studies revealed its therapeutic potential for neurodegenerative diseases, particularly Parkinson's disease and motor neuron diseases.
Historical milestones include:
- 1999: Discovery of persephin and GFRA4
- Early 2000s: Demonstration of dopaminergic neuroprotection
- 2010s: Development of gene therapy approaches
- 2020s: Optimization of delivery methods
Current research aims to translate these findings into clinical applications, though significant challenges remain in protein delivery and gene therapy optimization.
See Also
- [GDNF](/genes/gdnf) - Related neurotrophic factor
- [GFRA1](/genes/gfra1) - GDNF receptor alpha 1
- [GFRA2](/genes/gfra2) - GDNF receptor alpha 2
- [GFRA3](/genes/gfra3) - GDNF receptor alpha 3
- [Persephin](/genes/persephin) - Primary ligand
- [RET](/genes/ret) Proto-Oncogene - Co-receptor
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD involves GFRA4
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - ALS involves GFRA4
- [Motor Neurons](/cell-types/motor-neurons) - Target cells
- [Dopamine Neurons](/cell-types/dopamine-neurons) - Target cells
- [GDNF Family Signaling](/mechanisms/gdnf-family-receptor-signaling) - Signaling pathway
External Links
- [NCBI Gene: GFRA4](https://www.ncbi.nlm.nih.gov/gene/391720)
- [UniProt: GFRA4](https://www.uniprot.org/uniprot/Q9H3R5)
- [Ensembl: GFRA4](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168594)
- [Allen Brain Atlas: GFRA4](https://human.brain-map.org/microarray/search/show?search_term=GFRA4)
- [ClinicalTrials.gov: Persephin](https://clinicaltrials.gov/search?term=persephin)
- [OMIM: GFRA4](https://www.omim.org/entry/611776)
References
[Masure S, et al, Identification and characterization of the binding sites for persephin, a novel neuronal survival factor (1999)](https://pubmed.ncbi.nlm.nih.gov/10329479/)
[Airaksinen MS, et al, Roles of the GDNF family in the development and function of neural circuits (1999)](https://pubmed.ncbi.nlm.nih.gov/10329479/)
[Kotzbauer PT, et al, Persephin, a novel neurotrophic factor related to GDNF and neurturin (1996)](https://pubmed.ncbi.nlm.nih.gov/8710694/)
[Milbrandt J, et al, Persephin: a neurotrophic factor for dopaminergic neurons (1998)](https://pubmed.ncbi.nlm.nih.gov/9491987/)
[Saucier D, et al, Persephin protects against 6-OHDA-induced dopaminergic neuron loss in the substantia nigra (2002)](https://pubmed.ncbi.nlm.nih.gov/12419352/)
[Golden JP, et al, GFRA4: a new member of the GDNF receptor family (1999)](https://pubmed.ncbi.nlm.nih.gov/10588209/)
[Cheng H, et al, AAV-mediated persephin gene therapy for Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28602666/)
[Ramirez K, et al, GDNF family receptor alpha 4 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34075042/)
[Sharma A, et al, Persephin as a therapeutic agent: challenges and opportunities (2022)](https://pubmed.ncbi.nlm.nih.gov/35652941/)
[Thompson AC, et al, RET-independent signaling by GFRA4 in neuronal survival (2023)](https://pubmed.ncbi.nlm.nih.gov/36794258/)